|
[1]
|
Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 2025;31(S1):S32 − 50. |
|
[2]
|
Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes association. Diabetes Care 2025;48(7):1057 − 82. |
|
[3]
|
Shang Y, Grip ET, Modica A, Skröder H, Ström O, Ntanios F, et al. Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes. Diabetes Care 2024;47(6):978 − 85. |
|
[4]
|
Liu SH, Wan H, Yang L, Shen J, Qi XL. High prevalence of steatotic liver disease and fibrosis in the general population: a large prospective study in China. J Hepatol 2025;82(1):e23 − 5. |
|
[5]
|
Qi XL, Li J, Caussy C, Teng GJ, Loomba R. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatology 2024. http://dx.doi.org/10.1097/HEP.0000000000000913 |
|
[6]
|
Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 2024;22(10):1999 − 2010.e8. |
|
[7]
|
En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut 2023;72(11):2138 − 48. |
|
[8]
|
American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. Diabetes Care 2025;48(1 Suppl 1):S167-80. http://dx.doi.org/10.2337/dc25-S008. |
|
[9]
|
Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025;13(3):221 − 62. |
|
[10]
|
Park H, Cheuk-Fung Yip T, Yoon EL, Lai-Hung Wong G, Lee HS, Wai-Sun Wong V, et al. Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: a population-based multi-cohort study. JHEP Rep 2025;7(6):101388. |